Evaluating the impact of unmeasured confounding with internal validation data: An example cost evaluation in type 2 diabetes

Value in Health

Volumn 16, Issue 2, 2013, Pages 259-266

  Faries, Douglas ^a   Peng, Xiaomei ^a   Pawaskar, Manjiri ^a   Price, Karen ^a   Stamey, James D ^b   Seaman, John W ^b  

^a ELI LILLY AND COMPANY   (United States)

^b BAYLOR UNIVERSITY   (United States)

Author keywords

Bayesian methods; confounding; robustness; sensitivity analyses

Indexed keywords

ANTIDIABETIC AGENT;

ADULT; ARTICLE; BAYES THEOREM; CALIBRATION; FEMALE; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPENSITY SCORE; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS;

EID: 84875448813     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.10.012     Document Type: Article

References (32)

1. B. Motheral, J. Brooks, and M.A. Clark A checklist for retroactive database studies - report of the ISPOR Task Force on Retrospective Databases Value Health 6 2003 90 97
2. S. Crystal, A. Akincigil, S. Bilder, and J.T. Walkup Studying prescription drug use and outcomes with Medicaid claims data Med Care 45 Suppl 2007 S58 S65
3. P.R. Rosenbaum, and D.B. Rubin Reducing bias in observational studies using subclassification on the propensity score J Am Stat Assoc 79 1984 516 524
4. P.R. Rosenbaum Design of Observational Studies 2010 Springer New York
5. R.B. D'Agostino Jr Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
6. J. Concato, N. Shah, and R.I. Horowitz Randomized, controlled trials, observational studies, and the hierarchy of research designs N Engl J Med 342 2000 1887 1892
7. K. Benson, and A.J. Hartz A comparison of observational studies and randomized, controlled trials N Engl J Med 342 2002 1878 1886
8. J.P. Vandenbrouke Observational research, randomized trials, and two views of medical science PLoS Med 5 2008 e67
9. R.B. D'Agostino Jr, and R.B. D'Agostino Estimating treatment effects using observational data JAMA 297 2007 314 316
10. S. Schneeweiss Sensitivity analyses and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics Pharmacoepi Drug Safety 15 2006 291 303
11. P. Gustafson, and L.C. McCandless Probabilistic approaches to better quantifying the results of epidemiologic studies Int J Environ Res Pub Health 7 2010 1520 1539
12. L.C. McCandless, P. Gustafson, and A.R. Levy Bayesian sensitivity analysis for unmeasured confounding in observational studies Statist Med 26 2007 2331 2347
13. S. Schneeweiss, and P.S. Wang Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information J Am Geriatr Soc 53 2005 948 955
14. L.M. Bodnar, G. Tang, and R.B. Ness Periconceptional multivitamin use reduces the risk of preeclampsia Am J Epidemiol 164 2006 470 477
15. S. Schneeweiss, S. Setoguchi, and M.A. Brookhard Assessing residual confouding of the association between antipsychotic medications and risk of death using survey data CNS Drugs 23 2009 171 180
16. L.C. McCandless, P. Gustafson, and A.R. Levy A sensitivity analysis using information about measured confounders yielded improved assessments of uncertainty from unmeasured confounding J Clin Epidemiol 61 2008 247 255
17. T. Sturmer, S. Schneeweiss, J. Avorn, and R.J. Glynn Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibation Am J Epidemiol 162 2005 279 289
18. B. Crowe, I. Lipkovich, and O. Wang Comparison of several imputation methods for missing baseline data in propensity scores analysis of binary outcome Pharm Stat 9 4 2010 269 279
19. Y. Qu, and I. Lipkovich Propensity scoring with missing values D. Faries, A.C. Leon, J.M. Haro, R.L. Obenchain, Analysis of Observational Health Care Data Using SAS 2010 SAS Institute Cary, NC
20. T. Sturmer, S. Schneeweiss, and K.J. Rothman Performance of propensity score calibation - a simulation study Am J Epidemiol 165 2007 1110 1118
21. M. Pawaskar, A. Zagar, T. Sugihara, and L. Shi Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis J Med Econ 14 2011 16 27
22. S. Ramsey, R. Willke, and A. Briggs Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report Value Health 8 2005 521 533
23. J.A. Doshi, H.A. Glick, and D. Polsky Analysis of cost data in economic evaluations conducted alongside randomized controlled trials Value Health 9 2006 334 340
24. D.E. Faries, X. Peng, and R.L. Obenchain Costs and cost-effectiveness analyses using propensity score bin bootstrapping D. Faries, A.C. Leon, J.M. Haro, R.L. Obenchain, Analysis of Observational Healthcare Data Using SAS 2010 SAS Institute Cary, NC
25. W.G. Manning, A. Basu, and J. Mullahy Generalized modeling approaches to risk adjustment of skewed outcomes data J Health Econ 24 2005 465 488
26. Schafer Analysis of Incomplete Multivariate Data 1997 Chapman & Hall London
27. G. Oster, D. Thompson, and J. Edelsberg Lifetime health and economic benefits of weight loss among obese persons Am J Public Health 89 1999 1536 1542
28. A.P. Yu, E.Q. Wu, and H.G. Birnbaum Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data Curr Med Res Opin 23 9 2007 2157 2169
29. L.L. Nielsen, T. Okerson, J. Holcombe, and B. Hoogwerf Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes J Diabetes Sci Technol 2 2008 255 260
30. J. Trogdon, and T. Hylands Nationally representative medical costs of diabetes by time since diagnosis Diabetes Care 31 2008 2307 2311
31. R.J. Heine, L.F. Van Gaal, and D. Johns Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes Ann Intern Med 143 2005 559 569
32. M.A. Hernan, B. Brumback, and J.M. Robins Marginal structural models to assess the causal effect of zidovudine on the survival of HIV-positive men Epidemiology 11 2000 562 570